MINNEAPOLIS , March 31, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI ) (“POAI” or “the Company”), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced continued progress towards by its Helomics
MINNEAPOLIS , March 23, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for
MINNEAPOLIS , March 16, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for
With More Viral Outbreaks Expected, Predictive Oncology Expands AI Platforms to Aid in Vaccine and Drug Development MINNEAPOLIS , March 12, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“POAI” or “the Company”), a knowledge-driven company focused on applying artificial
POAI proposed acquisition of Carnegie Mellon University spin-out Quantitative Medicine further positions the company to aid in efforts to accelerate the discovery of new anti-cancers, anti-virals, antibiotics and vaccines MINNEAPOLIS , March 02, 2020 (GLOBE NEWSWIRE) -- Amid mounting concern over
MINNEAPOLIS , Feb. 21, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for
New Formulations Will Speed Discovery of Biomarkers and Precision Therapies MINNEAPOLIS , Feb. 05, 2020 (GLOBE NEWSWIRE) -- TumorGenesis, Inc. a subsidiary of Predictive Oncology, Inc. (NASDAQ: POAI) has selected US Biological Corporation of Salem, Massachusetts as the manufacturer and distributor
AI platform was developed at the Ray and Stephanie Lane Center for Computational Biology, which became the Computational Biology Department at Carnegie Mellon University and was successfully tested by several pharma companies MINNEAPOLIS , Jan. 24, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc.
MINNEAPOLIS , Jan. 06, 2020 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for
MINNEAPOLIS , Dec. 17, 2019 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI) (“Predictive Oncology” or “the Company”), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for